UK Lawmakers Caution UK Accords with President Trump are 'Built on Sand'.

Government ministers and leading parliamentarians have expressed alarm that the United Kingdom's recent agreements with Washington are "lacking a solid foundation." This stems from revelations that a much-touted deal on medicines, which commits to zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond broad headline terms contained within government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, promoted as a "significant" achievement, is still an "statement of intent" without formal ratification. Observers point out that the official announcements from the UK and US governments frame the deal in divergent terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement dwells on the commitment for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has promised concessions to increase medicine costs in return for little more than a verbal promise from President Trump," stated David Henig, a trade expert. "History shows he has a tendency for not keeping promises."

Broader Instability and a Paused Tech Deal

Worries have been intensified by Washington's move to pause the major technology agreement, which was previously described as "a huge leap forward" in the bilateral relationship. The US cited a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an initial accord have yet to be formally signed off by the US, despite a looming January deadline. "Our understanding is that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have voiced worries that the government's agreements with the US are flimsy and unreliable. One minister described the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, stated: "What is even more astonishing than Trump's temper tantrums is the UK government's credulous faith that his administration is a reliable partner. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have downplayed the chances of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that unpredictability is a feature of dealing with the current US leadership. However, they contend that the UK has secured concrete outcomes for businesses, such as preferential tariff rates compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, issues have surfaced in implementing the broader trade deal. Promised reciprocal agricultural allowances have yet to be finalized, and the assurance to "eliminate duties on UK metals" has not been fulfilled, with tariffs fixed at 25%.

Looking ahead, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.